Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".
- Published in:
- 2014
- By:
- Publication type:
- Letter
Works matching IS 11707690 AND DT 2014 AND VI 32 AND IP 12
Results: 14
1
2
Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".
- Published in:
- 2014
- By:
- Publication type:
- Letter
3
A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1157, doi. 10.1007/s40273-014-0193-3
- By:
- Publication type:
- Article
4
A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1185, doi. 10.1007/s40273-014-0197-z
- By:
- Publication type:
- Article
5
A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1201, doi. 10.1007/s40273-014-0198-y
- By:
- Publication type:
- Article
6
The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1213, doi. 10.1007/s40273-014-0199-x
- By:
- Publication type:
- Article
7
'Can We Declare Victory and Move On?' The Case Against Funding Burden-of-Disease Studies.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1153, doi. 10.1007/s40273-014-0200-8
- By:
- Publication type:
- Article
8
Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1231, doi. 10.1007/s40273-014-0207-1
- By:
- Publication type:
- Article
9
Cost of Illness: An Ongoing Battle Worth Fighting.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1151, doi. 10.1007/s40273-014-0217-z
- By:
- Publication type:
- Article
10
Comment on: 'Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines'.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1245, doi. 10.1007/s40273-014-0221-3
- By:
- Publication type:
- Article
11
Authors' Reply to Gandjour: 'Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines'.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1247, doi. 10.1007/s40273-014-0232-0
- By:
- Publication type:
- Article
12
Objectivity and Equity: Clarity Required. A Response to Hill and Olson.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1249, doi. 10.1007/s40273-014-0239-6
- By:
- Publication type:
- Article
13
Acknowledgements.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1147, doi. 10.1007/s40273-014-0240-0
- Publication type:
- Article
14
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 12, p. 1171, doi. 10.1007/s40273-014-0189-z
- By:
- Publication type:
- Article